Pharmaceutical

Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma

The MAGE-A4-targeted genetically modified T cell therapy is indicated for the treatment of synovial sarcoma.

Aug 3, 2024 - 04:00
Adaptimmune’s Tecelra gains accelerated approval for synovial sarcoma
The MAGE-A4-targeted genetically modified T cell therapy is indicated for the treatment of synovial sarcoma.
Read the original article

Tags:

Previous Article

Vir Bio trims staff and pipeline to focus on Sanofi-licensed programmes

Next Article

Casgevy: Launch sequence and price analysis of the first marketed CRISPR therapy

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Overcoming the added patient burden in DCTs

Overcoming the added patient burden in DCTs

Apr 3, 2024

Twist Bioscience and Bayer partner for antibody discovery

Twist Bioscience and Bayer partner for antibody discovery

Oct 7, 2023

STAT+: What to know about this summer’s landmark Wegovy heart health study

STAT+: What to know about this summer’s landmark Wegovy...

Jul 6, 2023